| Vol. 14.23 – 23 June, 2022 |
| |
|
|
| MSCs were isolated from human placenta tissue, and DF-MSCs or Gluc-MSCs were generated by transduced with firefly luciferase/enhanced green fluorescence protein or Gaussia luciferase lactadherin fusion protein. [Stem Cell Research & Therapy] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Human umbilical cord-derived MSCs not only ameliorated blood glucose but also protected vascular endothelium from diabetic damage, in which MAPK/ERK signaling mediated its molecular mechanism of paracrine action. [Stem Cell Research & Therapy] |
|
|
|
| Investigators explored whether long-term inhibition of inflammation could successfully alleviate high-fat diet-induced obesity. [Stem Cell Research & Therapy] |
|
|
|
| To clarify the function of DCAF2 in vivo, scientists used Cre recombinase driven by the Elf5 promoter to generate knockout mouse model that was specifically deleted Dcaf2 in the trophoblast lineage (Elf5-Cre; Dcaf2fl/fl, Dcaf2 cKO). [Cell and Tissue Research] |
|
|
|
| Human umbilical cord mesenchymal stem cell (HUCMSC)-derived exosomes diminished NOTCH1 expression to accelerate M2 macrophage polarization via delivery of miR-146a-5p, thus alleviating systemic lupus erythematosus-associated diffuse alveolar hemorrhage in mice. [Immunological Investigations] |
|
|
|
| Researchers highlighted that miR-22 and miR-372 could improve glucose metabolic disorders in gestational diabetes mellitus (GDM) and might serve as diagnostic biomarkers for GDM as well as promising therapeutic targets for the treatment of this condition. [Journal of Clinical Laboratory Analysis] |
|
|
|
|
| Due to the novelty of the field of using 3D culture MSCs-derived exosomes, examination of their properties and the results of their therapeutic application can increase our view of this field. [Biomedicine & Pharmacotherapy] |
|
|
|
|
| Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced Aziyo co-founder C. Randal Mills, Ph.D., has been appointed interim president and CEO. [Aziyo Biologics, Inc.] |
|
|
|
|
| December 3-7, 2022 Washington, DC, United States |
|
|
|
|
|
| Luna Genetics, Inc. – Houston, Texas, United States |
|
|
|
| Van Andel Institute – Grand Rapids, Michigan, United States |
|
|
|
| New York University College of Dentistry – New York, New York, United States |
|
|
|
| Albert Einstein College of Medicine – New York, New York, United States |
|
|
|
| Flanders Institute for Biotechnology – Antwerp, Belgium |
|
|
|
|